2025年港股市场表现亮眼，恒生指数与恒生科技指数领跑全球主要股票市场。博道基金基金经理张建胜 作为A+H两地布局的成长型基金经理，早在2024年一季度就提前布局、坚定加仓港股，他的投资逻辑 主要围绕估值性价比和结构变化展开。 张建胜在接受证券时报记者采访时表示，截至目前，港股的整体估值并不算贵，后续或仍将受益于国内 经济企稳回升和美联储降息。得益于前瞻性的布局，他成功捕捉了本轮创新药板块的上涨行情。张建胜 坦言，从价值低估到估值修复阶段的投资相对容易把握，他将此形象地比喻为"一眼见胖瘦"；但要获取 企业持续成长带来的红利，则需跨越更高的研究壁垒。 在景气度方面，针对A股的TMT公司，景气度的权重则相对会高一点。 左侧买左侧卖 作为拥有绝对收益思维的成长风格基金经理，张建胜的投资方法论可概括为三大核心特点：第一，风格 偏成长，组合持仓一直是成长风格的3个方向，包括高端制造、TMT和泛消费；第二，均衡投资，不押 赛道，单一行业（申万一级）持仓不超过25%；第三，自下而上，适度逆向，看重估值。 张建胜坦言自己不太擅长周期风格，偏稳定类的比如过去三四年表现比较好的红利，持仓也没有超过 10%。他表示，与其他的成长风 ...

Group 1 - Public funds in the pharmaceutical sector have shown significant excess returns, with an average net value growth rate exceeding 19% as of June 18, making it a market focus [1][3] - The average net value growth rate for all public funds is 2.83%, while over 260 pharmaceutical-related funds have achieved an average growth rate of 19.66%, indicating strong profitability [1][3] - Among the top 100 funds by performance, pharmaceutical funds occupy 49 positions, highlighting their strong earning effect [1] Group 2 - Funds specifically focused on "innovative drugs" have performed exceptionally well, with an average net value growth rate of 27.68%, and 21 funds exceeding 20% growth [3] - Key factors driving the strong performance of the pharmaceutical sector, particularly innovative drugs, include supportive policies such as improved drug procurement mechanisms and accelerated new drug approvals [3] - The period from 2025 to 2028 is critical for Chinese innovative drug companies to enter profitability, with 2025 being a pivotal year for the industry [3] Group 3 - Increased collaboration between domestic innovative drug companies and multinational pharmaceutical firms reflects the global competitiveness of China's innovative drug sector [4] - Fund managers are optimistic about the long-term investment value of the innovative drug sector, citing improved valuation post-adjustment and enhanced R&D efficiency due to domestic talent [3][4] - The government’s influence on drug procurement is diminishing, further supporting the growth potential of the innovative drug sector [3]

Group 1 - The core viewpoint is that pharmaceutical funds have significantly outperformed the market, with an average net value growth rate of over 19% as of June 18, making them a focal point for investors [1][2] - Among all public funds, pharmaceutical funds accounted for 49 out of the top 100 funds in terms of performance, indicating strong interest and investment potential in this sector [2] - The average net value growth rate for pharmaceutical funds reached 19.66%, with several funds achieving around 70% growth, particularly those focused on innovative drugs [2] Group 2 - Key driving factors for the pharmaceutical sector's performance include supportive policies such as improved drug procurement mechanisms and accelerated new drug approval processes [3] - The period from 2025 to 2028 is projected to be critical for Chinese innovative drug companies, with 2025 expected to be a pivotal year for profitability [3] - The innovative drug sector is anticipated to enter a sustained growth cycle, driven by clinical catalysts and significant financial performance improvements [3] Group 3 - Fund managers express optimism about the innovative drug sector, highlighting its growth potential and the favorable policy environment that provides substantial development space for pharmaceutical companies [4] - The innovative drug sector is seen as undervalued, with many companies now presenting attractive valuations, leading to increased investment interest [4] - Recent performance in the innovative drug sector is attributed to the market's recognition of the value of high-quality Chinese innovative drug assets [4] Group 4 - Collaborations between domestic innovative drug companies and multinational pharmaceutical firms are enhancing the global competitiveness of Chinese innovative drugs, prompting a reassessment of their pipeline values [5]